Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IMV (IMVResearch Report), Cullinan Management (CGEMResearch Report) and Prelude Therapeutics (PRLDResearch Report) with bullish sentiments.

IMV (IMV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV today and set a price target of $13.00. The company’s shares closed last Thursday at $1.29, close to its 52-week low of $1.05.

According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -21.3% and a 23.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Currently, the analyst consensus on IMV is a Moderate Buy with an average price target of $7.19.

See today’s best-performing stocks on TipRanks >>

Cullinan Management (CGEM)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Cullinan Management, with a price target of $53.00. The company’s shares closed last Thursday at $12.03, close to its 52-week low of $11.52.

According to TipRanks.com, White is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.1% and a 25.3% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

Cullinan Management has an analyst consensus of Moderate Buy, with a price target consensus of $44.50.

Prelude Therapeutics (PRLD)

Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Prelude Therapeutics today and set a price target of $19.00. The company’s shares closed last Thursday at $8.09, close to its 52-week low of $6.76.

According to TipRanks.com, Hung is a 5-star analyst with an average return of 21.9% and a 56.0% success rate. Hung covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Ultragenyx Pharmaceutical, and Bicycle Therapeutics.

Currently, the analyst consensus on Prelude Therapeutics is a Moderate Buy with an average price target of $13.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on IMV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos